The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：520

作者：

Yuan, Min ^{[1
,2
]}

Huang, Li-Li ^{[1
,2
]}

Chen, Jian-Hua ^{[1
,3
]}

Wu, Jie ^{[3
,4
]}

Xu, Qing ^{[1
,2
]}

机构：

[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China

[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China

[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA

[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期

基金：

中国国家自然科学基金;

关键词：

EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;

D O I：

10.1038/s41392-019-0099-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

引用

页数：14

共 160 条

[81] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[82] miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR [J].

Ma, Hui-Ping ;

Kong, Wei-Xiang ;

Li, Xiu-Ying ;

Li, Wei ;

Zhang, Yan ;

Wu, Yan .

ONCOLOGY REPORTS, 2019, 41 (03) :1549-1559

[83] Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy [J].

Ma, Weijie ;

Gilligan, Barbara M. ;

Yuan, Jianda ;

Li, Tianhong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

[84] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[85] Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds [J].

Malm, Magdalena ;

Frejd, Fredrik Y. ;

Stahl, Stefan ;

Lofblom, John .

MABS, 2016, 8 (07) :1195-1209

[86] KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].

Massarelli, Erminia ;

Varella-Garcia, Marileila ;

Tang, Ximing ;

Xavier, Ana C. ;

Ozburn, Natalie C. ;

Liu, Diane D. ;

Bekele, Benjamin N. ;

Herbst, Roy S. ;

Wistuba, Ignacio I. .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :2890-2896

[87] 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+NSCLC (POPLAR) [J].

Mazieres, J. ;

Park, K. ;

Lewanski, C. ;

Gadgeel, S. ;

Fehrenbacher, L. ;

Rittmeyer, A. ;

Han, J-Y. ;

Artal-Cortes, A. ;

Braiteh, F. ;

Vansteenkiste, J. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) :S79-S79

[88] Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity [J].

Meulendijks, Didier ;

Jacob, Wolfgang ;

Voest, Emile E. ;

Mau-Sorensen, Morten ;

Martinez-Garcia, Maria ;

Taus, Alvaro ;

Fleitas, Tania ;

Cervantes, Andres ;

Lolkema, Martijn P. ;

Langenberg, Marlies H. G. ;

De Jonge, Maja J. ;

Sleijfer, Stefan ;

Han, Ji-Youn ;

Calles, Antonio ;

Felip, Enriqueta ;

Kim, Sang-We ;

Schellens, Jan H. M. ;

Wilson, Sabine ;

Thomas, Marlene ;

Ceppi, Maurizio ;

Meneses-Lorente, Georgina ;

James, Ian ;

Vega-Harring, Suzana ;

Dua, Rajiv ;

Nguyen, Maitram ;

Steiner, Lori ;

Adessi, Celine ;

Michielin, Francesca ;

Bossenmaier, Birgit ;

Weisser, Martin ;

Lassen, Ulrik N. .

CLINICAL CANCER RESEARCH, 2017, 23 (18) :5406-5415

[89] First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors [J].

Meulendijks, Didier ;

Jacob, Wolfgang ;

Martinez-Garcia, Maria ;

Taus, Alvaro ;

Lolkema, Martijn P. ;

Voest, Emile E. ;

Langenberg, Marlies H. G. ;

Fleitas Kanonnikoff, Tania ;

Cervantes, Andres ;

De Jonge, Maja J. ;

Sleijfer, Stefan ;

Soerensen, Morten Mau ;

Thomas, Marlene ;

Ceppi, Maurizio ;

Meneses-Lorente, Georgina ;

James, Ian ;

Adessi, Celine ;

Michielin, Francesca ;

Abiraj, Keelara ;

Bossenmaier, Birgit ;

Schellens, Jan H. M. ;

Weisser, Martin ;

Lassen, Ulrik N. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :877-885

[90] Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial [J].

Miller, Vincent A. ;

Hirsh, Vera ;

Cadranel, Jacques ;

Chen, Yuh-Min ;

Park, Keunchil ;

Kim, Sang-We ;

Zhou, Caicun ;

Su, Wu-Chou ;

Wang, Mengzhao ;

Sun, Yan ;

Heo, Dae Seog ;

Crino, Lucio ;

Tan, Eng-Huat ;

Chao, Tsu-Yi ;

Shahidi, Mehdi ;

Cong, Xiuyu Julie ;

Lorence, Robert M. ;

Yang, James Chih-Hsin .

LANCET ONCOLOGY, 2012, 13 (05) :528-538

← 4 5 6 7 8 9 10 11 12 13 →